Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.41 |
| ▸ | MAOA | P21397 | 5/20 | 0.41 |
| ▸ | ANPEP | P15144 | 6/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | AOC2 | O75106 | 4/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1783171 | 0.74 | MAOB (0.43) | MAOBMAOAANPEPCYP1A2KDM4E | |
| SCHEMBL7664111 | 0.74 | MAOB (0.43) | MAOBMAOAANPEPCYP1A2KDM4E | |
| SCHEMBL2424577 | 0.74 | TSHR (0.48) | MAOBMAOAANPEPCYP1A2KDM4E | |
| SCHEMBL19746 | 0.71 | CYP19A1 (0.45) | MAOBMAOAANPEPKDM4EADORA3 | |
| SCHEMBL30292163 | 0.70 | SMN1; SMN2 (0.42) | MAOBMAOAANPEPKDM4EADORA3 | |
| SCHEMBL8823819 | 0.70 | MAOB (0.39) | MAOBMAOAANPEPCYP1A2KDM4E | |
| SCHEMBL5328708 | 0.70 | SMN1; SMN2 (0.42) | MAOBMAOAANPEPKDM4EADORA3 | |
| SCHEMBL11733122 | 0.70 | CYP19A1 (0.44) | MAOBMAOAANPEPKDM4EADORA3 | |
| SCHEMBL8496949 | 0.70 | MAOB (0.39) | MAOBMAOAANPEPCYP1A2KDM4E | |
| SCHEMBL28904739 | 0.70 | CA2 (0.37) | MAOBMAOAANPEPKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8632792-B2 | Cooling sensation agent composition and sensory stimulation agent composition | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2014-01-21 | — | — | US | disclosed |
| US-20110117147-A1 | COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-05-19 | — | — | US | disclosed |
| WO-2009123355-A2 | COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-10-08 | — | — | WO | disclosed |
| EP-1033369-B1 | 5H-PYRANO [2,3-d:6,5-d']DIPYRIMIDINE DERIVATIVES HAVING AN ANTIBACTERIAL, ANTIVIRAL AND IMMUNO-MODULATING ACTIVITY | NATURAL DRUG SCIENCES L L C (US) | 2003-01-29 | — | — | EP | disclosed |
| US-6340755-B1 | IMMUNOMMODULATORS, BACTERICIDES AND VIRICIDES | NATURAL DRUG SCIENCES LLC | 2002-01-22 | — | — | US | disclosed |
| EP-1033369-A1 | 5H-PYRANO [2,3-d:6,5-d']DIPYRIMIDINE DERIVATIVES HAVING AN ANTIBACTERIAL, ANTIVIRAL AND IMMUNO-MODULATING ACTIVITY | Tets, Viktor Veniaminovich (RU) | 2000-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117147-A1 | COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION | TRPA1, HRH1, HRH2 | MAOB 3615/4885MAOA 2700/4885ANPEP 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.